Expect to See Crizanlizumab or Voxelotor for Some Sickle Cell Patients

Crizanlizumab (Adakveo, ah-DAK-vee-oh) and voxelotor (Oxbryta, oks-BRYE-tuh) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they’ll compete with oral L-glutamine (Endari)...which seems to reduce pain crises and possibly hospitalizations.

Get unlimited access through an Enterprise license

Hospital Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals